🔗 Share this article Patients Discontinuing Anti-Obesity Medications Gain Back Weight Four Times Faster Compared to People Using Diet and Exercise Obesity treatment involves ongoing approaches. A recent study reveals that patients who discontinue popular GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise plans. Research printed in a prominent medical journal points out that while obese individuals can lose substantial amounts of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation. "Users purchasing such medications should be cognizant of the danger of fast rebound weight gain when the treatment ends," warns researcher Dr. Susan Jebb. Such speed of regain suggests a return to pre-treatment weight within about one and a half years. Comparing Therapies The analysis, which looked at 37 of trials involving thousands of participants, contrasted the outcomes of the injectable medications with older methods. Researchers note that people who lose weight through diet and exercise typically experience a slower weight regain—approximately 0.1 kg a month—post-intervention. Explaining the Fast Regain Experts suggest the mechanism of the drugs explains the heightened regain. These medications copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness. "Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist. "Withdrawal of this hormone supplement results in hunger is uncontrolled, making binge eating a significant risk." A Lifelong Issue? Medical guidelines recommend the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications. Professionals argue that, considering the high risk of weight regain, the treatment is often life-long. This opinion is supported by pharmaceutical companies, who note that the findings "highlight the long-term nature of excess weight," similar to managing diseases like hypertension. User Testimonies Individuals who have stopped the medication describe a powerful resurgence of cravings. "It was like something flipping and I was suddenly starving," recalled an individual. This difficulty is worsened if users have not established permanent lifestyle or habit changes during treatment. Growing Adoption Recent estimates show that millions of adults in the UK have tried these injections in the past year, with interest continuing to grow. Use is greater among women than males. The 40s and 50s demographic shows the greatest level of interest. A large proportion obtain the drugs through private healthcare rather than public health services. Ultimately, experts caution that while these medications are powerful tools for weight loss, they are not a permanent fix and maintained weight loss likely depends on ongoing lifestyle changes.
Obesity treatment involves ongoing approaches. A recent study reveals that patients who discontinue popular GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise plans. Research printed in a prominent medical journal points out that while obese individuals can lose substantial amounts of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation. "Users purchasing such medications should be cognizant of the danger of fast rebound weight gain when the treatment ends," warns researcher Dr. Susan Jebb. Such speed of regain suggests a return to pre-treatment weight within about one and a half years. Comparing Therapies The analysis, which looked at 37 of trials involving thousands of participants, contrasted the outcomes of the injectable medications with older methods. Researchers note that people who lose weight through diet and exercise typically experience a slower weight regain—approximately 0.1 kg a month—post-intervention. Explaining the Fast Regain Experts suggest the mechanism of the drugs explains the heightened regain. These medications copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness. "Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist. "Withdrawal of this hormone supplement results in hunger is uncontrolled, making binge eating a significant risk." A Lifelong Issue? Medical guidelines recommend the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications. Professionals argue that, considering the high risk of weight regain, the treatment is often life-long. This opinion is supported by pharmaceutical companies, who note that the findings "highlight the long-term nature of excess weight," similar to managing diseases like hypertension. User Testimonies Individuals who have stopped the medication describe a powerful resurgence of cravings. "It was like something flipping and I was suddenly starving," recalled an individual. This difficulty is worsened if users have not established permanent lifestyle or habit changes during treatment. Growing Adoption Recent estimates show that millions of adults in the UK have tried these injections in the past year, with interest continuing to grow. Use is greater among women than males. The 40s and 50s demographic shows the greatest level of interest. A large proportion obtain the drugs through private healthcare rather than public health services. Ultimately, experts caution that while these medications are powerful tools for weight loss, they are not a permanent fix and maintained weight loss likely depends on ongoing lifestyle changes.